Paracetamol, Ibuprofen May Soon Be Available At General Stores As India Reviews First List Of OTC Drugs
Last Updated:
A committee has proposed that India needs to develop legal provisions, eligibility for considering drug as OTC and special labelling similar to those for prescription medicines
A total of 27 prescription-only medicines, including levocetrizine, ibuprofen and paracetamol will soon be sold at medical and general stores as over-the-counter (OTC) drugs, News18 has learnt.
The list of 27 drugs includes the names of generic formulations and the strength of doses allowed to be sold without a prescription.
Currently, India lacks a comprehensive set of regulations governing the distribution, marketing, and consumption of OTC drugs. In May, drug regulator Central Drugs Standard Control Organisation (CDSCO) constituted a sub-committee to examine matters regarding the amendment of the Drugs Rules to incorporate necessary provisions for drugs to be declared as over-the-counter (OTC), in line with a recommendation of the Drugs Technical Advisory Board (DTAB) meeting. Now, the panel has submitted the report, and DTAB will deliberate to move on moving forward.
'The subcommittee has finely balanced and submitted the report containing almost 27 generic names of formulations for the top therapeutic segment. These formulations are top-selling and best in the safety profile of that category. For instance, Levocetirizine is best to treat allergies, ibuprofen is best for painkillers and paracetamol for anti-pyretic use," a senior official at the Ministry of Health and Family Welfare, privy to the development, told News18.
The sub-panel has also mentioned the strength of the medicines which should be available in the OTC category. 'It would be damaging if people end up popping painkiller ibuprofen in higher doses. Hence, the idea is to keep the moderate or mild dose available without prescription."
'Legal provisions to be enabled under Drugs Rules, 1945 along with the manner of submitting application, requirements for considering a drug as an OTC, Labelling requirements, etc and incorporation of a separate Schedule as enumerated under section 7 of the report," said the government document containing agenda for discussion on upcoming DTAB meeting.
The DTAB meeting is expected to convene in April. However, the final decision may take several meetings as the central government needs to design a full plan before it decides to shift prescription medicines into the OTC category.
The sub-committee was headed by Dr Anupam Prakash, Director and Professor of Medicine, Lady Hardinge Medical College, Delhi. The panel has other members including as Dr Umesh D Suranagi from Director General of Health Services (DGHS), Paediatrician Dr Ratan Kumar Gupta from Vardhman Mahavir Medical College & Safdarjung Hospital and Dr Bikash Medhi, Department of Pharmacology, Post Graduate Institute of Medical Education & Research (PGIMER).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
15 hours ago
- News18
Bharat Biotech's Nasal Vaccine 'Can Adapt' To New COVID Strains, Regulatory Nod Awaited
Last Updated: Bharat Biotech told News18 that the company's COVID-19 vaccine platforms are enabled for 'adaptation'. However, restarting production needs regulatory agency approvals. Amid rising concerns over the JN.1 COVID-19 variant, Indian vaccine maker Bharat Biotech has stated its preparedness to address the emerging variant with its 'adaptable" vaccine platforms. However, production will only restart with regulatory approval. Suchitra Ella, Managing Director of Bharat Biotech, told News18 that the company is 'actively monitoring the ongoing situation" and remains prepared to respond, emphasising the adaptability of its vaccine platforms to evolving strains. 'We remain committed to ensuring that our vaccine platforms are adaptable and ready to respond to evolving strains," she said. As of 11 June, India has recorded 7,121 active COVID-19 cases, according to the Union Health Ministry's official COVID-19 dashboard. Delhi, Gujarat, Kerala, Maharashtra, and West Bengal report the majority of these cases. Highlighting the benefits of its nasal vaccine, iNCOVACC, Ella told News18 that its intranasal COVID-19 vaccine offers targeted upper respiratory tract protection, ease of administration without needles, and adaptability to circulating strains. The company affirms its proactive monitoring and preparedness: 'actively monitoring the situation and well-positioned to respond effectively if the need arises." iNCOVACC, India's first intranasal COVID-19 vaccine, is available as a booster dose for adults. Its needle-free design, with drops instilled into each nostril, eliminates the need for trained healthcare professionals for administration. Ella confirmed the adaptability of both the injectable and intranasal COVID-19 vaccine platforms. 'However, any decision to restart production is contingent upon regulatory agency approvals. We continue to work in close coordination with regulatory bodies to ensure preparedness always aligns with evolving scientific and safety standards," she explained in an emailed interview with News18. While several countries recommend booster doses for high-risk and vulnerable groups, experts in India have not yet issued such a recommendation. 'Booster doses have been recommended in several countries for high-risk and vulnerable populations. Booster doses in our country are subject to approval from national regulatory agencies." Ella clarified that COVID-19 vaccine production would only recommence if directed by the national regulatory body. She also revealed the extent of vaccine wastage due to declining demand: 'As of early 2022, production of COVAXIN was paused in response to reduced demand and the cancellation of issued purchase orders. Subsequently, we proceeded with the destruction of around 20 crore doses of bulk and almost 5 crore doses of vaccines in vials." A senior health ministry source informed News18 that the recent rise in COVID-19 cases is no cause for panic, likening the current trend to seasonal influenza. While no immediate vaccination is necessary, basic precautions are advised, especially for those exhibiting symptoms. 'Wear a mask if you have a cough or cold, and request those around you to do the same, and people with co-morbidities like diabetes or kidney disease should remain particularly cautious during this period." Although booster shots may not be currently necessary in India, given the mild, influenza-like illness caused by current variants, the preparedness of Indian vaccine companies and their adaptable platforms demonstrate the nation's capacity for rapid response should more severe COVID-19 variants or other pathogens emerge.
News18
2 days ago
- News18
‘Revamp E-Prescription Rules': Chemist Lobby Asks For Mandatory ‘Dispensed' Stamp To Curb Re-Use
Last Updated: The letter flagged that a patient could use the same prescription as a soft copy or a printout of the soft copy at different pharmacies to repeatedly purchase the same medicines The Indian Pharmaceutical Association (IPA) has written to the apex drug regulator demanding 'urgent modifications" to the current rules governing e-prescribing and e-prescriptions to 'prevent inconvenience, misuse and contravention of laws". In a detailed letter, seen by News18, the lobby of pharmacists has pointed out loopholes in the country's telemedicine practice guidelines and the health ministry's e-Sanjeevani guidelines. The letter sent to the Drugs Controller General of India (DCGI) on June 9 highlights concerns regarding the current guidelines, which allow prescriptions to be sent directly to patients following teleconsultations. 'The issue is that the same prescription, as a soft copy or a printout of the soft copy, could be shown or used by the patient at different pharmacies to repeatedly purchase the same medicines listed on it. This can lead to repeat dispensing and misuse and is detrimental to public health," the letter said. It added that current guidelines lack 'any means of checking, confirming, or stopping this". The IPA has called for the Drugs & Cosmetics Act and Rules to be revised so that 'the pharmacist must put a 'Dispensed' stamp on an original printout of the prescription," and that this provision be expanded to cover e-prescriptions as well. Adapt the global ecosystem According to the letter, which is also sent to the Directorate General of Health Services (DGHS) and the Pharmacy Council of India (PCI), e-prescribing systems are globally proven to enhance efficiency and safety, but India must tailor its approach to local conditions. The letter cites the example of Australia, stating that the country also introduced electronic prescribing in May 2020 after they built a robust system that allows doctors to electronically prescribe medications to patients in the form of an encrypted QR code or text message. The catch here is that upon visiting the pharmacy of his choice, the patient shows the QR Code or text message, and the pharmacy scans it. Following this, the prescription is generated. 'The safety factor here is that the patient cannot repeatedly use the same prescription," the letter said. What should India do? 'We request you to please understand the situation: Very often, such e-prescriptions will be from doctors who are not from the patient's city or state. The pharmacist to whom the patient brings the prescription is in a dilemma as to whether the prescription is authentic or not." To eliminate such ambiguity, the IPA in the letter suggests a systemic overhaul. 'The law must mandate that the doctor either electronically send the prescription directly to the pharmacy or provide it in an encrypted mode to the patient, which only a pharmacy can decode, and not the patient." Highlighting the role of the Ayushman Bharat Digital Mission (ABDM), one of the flagship schemes of the Modi government, the letter said, 'The ABDM is already in the process of providing unique identities to pharmacies and pharmacists; integrating the receipt and access of e-prescriptions should be a natural extension of this initiative." Experts hold a different view While the IPA has called for a system that withholds direct prescription access from consumers, experts News18 spoke to hold a different view. 'The intention of IPA is in the right direction, but it won't be correct to take away the rights of patients. This will shift all power into the hands of pharmacists and pharmacies," said a former official from the National Medical Council (NMC) who was part of the panel framing the telemedicine guidelines. Echoing a similar observation, another official, an industry veteran running a successful e-pharmacy firm, told News18 that the suggestion 'restricts choice for a consumer and structurally will create a doctor-pharmacy nexus, taking away the freedom of choice from a consumer". 'Also, if the pharmacy to which the prescription goes does not have all the medicines in the prescription, which is very normal – then the consumer has no method of access," he said, adding that the pharmacies have no incentive to provide service and affordability to the patients since the consumer is helpless and dependent on them. Location : New Delhi, India, India First Published: June 10, 2025, 09:36 IST News india 'Revamp E-Prescription Rules': Chemist Lobby Asks For Mandatory 'Dispensed' Stamp To Curb Re-Use
News18
3 days ago
- News18
India Bets On Jan Aushadhi Kendras For HPV Vaccine To Prevent Cervical Cancer, Adds 116 New Drugs
Last Updated: The list also includes medicines for heart diseases, diabetes, epilepsy, apart from various other types of cancers The government's plan a roll out a nationwide HPV vaccination drive for girls to prevent cervical cancer remains stalled due to insufficient vaccine stock. To tide over the problem, the Narendra Modi government's flagship affordable generic drugs scheme, Jan Aushadhi, has now decided to include the HPV or Human Papillomavirus among 116 new medicines being added to its portfolio. The final list of medicines, accessed by News18, lists the recombinant HPV quadrivalent vaccine, which is effective against diseases caused by HPV types 6, 11, 16, and 18. '…used for the prevention of HPV-associated cancers, such as cervical, vaginal, vulvar, and anal cancer", mentions the document in the category of usage of the drug. The vaccine is expected to be available at subsidised rates through Jan Aushadhi outlets. The objective of the planned offering is to offer timely access, even as the national rollout remains uncertain. 'While the meeting to discuss the status of the roll-out of the nationwide HPV vaccination campaign for girls (aged 9 to 14 years) is expected to take place during the last week of June, there is no update from the Serum Institute of India (SII) on the requested quantity of vaccine doses. Without them, we cannot decide timelines or go ahead," a senior government official told News18. Meanwhile, the Union government is trying to expand access to HPV vaccines via Prime Minister Narendra Modi's flagship Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP). 'The scheme has just rolled out the tender for marketing the HPV vaccine as part of the initiative to add 116 more medicines to its existing bouquet of over 2,100 drugs and 315 surgical and medical devices," another senior government official said, adding that the price of the vaccine available at Jan Aushadhi retail outlets may not be steeply discounted. However, it remains unclear how the tendering procedure will work as in India, only the Serum Institute of India is currently the licensed manufacturer of the HPV vaccine. For the private market in India, the HPV vaccine from SII — Cervavac — typically costs Rs 4,000 per dose. Other Medicines on the List The Jan Aushadhi scheme offers generic drugs priced at 50–90 per cent lower than their branded counterparts in the market. The new list of medicines will be available at 16,500 Jan Aushadhi Kendras across India by September. 'It takes three to six months to complete the procurement procedure and bring medicines onto the retail shelf. The list was finalised in March, and now the tendering process is underway," the second official said. A significant portion of the medicines being added are for the treatment of heart disease and diabetes — two of India's most pressing health challenges. While India is often called the 'Diabetes Capital of the World,' with over 74 million adults affected, it also accounts for approximately 60 per cent of the world's heart disease burden. The list also includes several cancer drugs, including Ibrutinib, used in the treatment of blood cancer and costing between Rs 7,000 and Rs 9,500, which severely hurts the pocket of middle and lower-income class patients and families. Also, the list includes Abiraterone Acetate, a drug used in the treatment of prostate cancer, blood cancer, Hodgkin's disease, and also prescribed in some cases of sickle cell anaemia. A bottle of 60 tablets of the drug costs around Rs 35,000. With inclusion under the scheme, the prices of these drugs—in their generic version—are expected to fall by at least 50 per cent. Several other drugs for therapeutic categories such as the central nervous system, epilepsy and seizures, chronic obstructive pulmonary disease (COPD), anti-allergy and bone deficiencies are also part of the list. In March, Union health minister JP Nadda said the scheme is helping over 10 lakh people access affordable medicines, leading to cumulative savings of Rs 30,000 crore. While the scheme has been helping those, who cannot afford branded medicines, if it manages to offer quality cancer drugs and the HPV vaccine at discounted prices, it could set a significant benchmark for public health affordability and access. First Published:
